Brief Report
International Journal of Impotence Research (2007) 19, 104–107. doi:10.1038/sj.ijir.3901483; published online 18 May 2006
Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study
M Nickel1,2, D Moleda1, T Loew3, W Rother1 and F Pedrosa Gil4
- 1Clinic for Psychosomatic, Inntalklinik, Simbach/Inn, Germany
- 2University Clinic for Psychiatry 1, PMU, Salzburg, Austria
- 3Department of Psychosomatic Medicine, Regensburg University Clinic, Regensburg, Germany
- 4Psychosomatic Outpatient Clinic, University Medicine Clinic, LMU, Munich, Germany
Correspondence: Dr M Nickel, Psychosomatics, Inntalklinik, Jakob-W.1, Simbach am Inn, 84359, Germany. E-mail: m.nickel@inntalklinik.de
Received 20 February 2006; Revised 15 March 2006; Accepted 24 March 2006; Published online 18 May 2006.
Abstract
The effectiveness of cabergoline in 50 men with psychogenic erectile dysfunction was investigated in a 4-month, randomized, placebo-controlled, double-blind study with validated psychological tests, and prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone serum levels. Cabergoline treatment was well-tolerated and resulted in normalization of hormone levels in most cases. In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Erectile function improved significantly. Sexual desire, orgasmic function, and the patient's and his partner's sexual satisfaction were also enhanced. Cabergoline may be an effective and safe alternative agent for men with psychogenic ED.
Keywords:
psychogenic erectile dysfunction, libido, cabergoline, prolactin, testosterone, quality of life
